

ABSTRACT OF THE DISCLOSURE

The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.

| Group | Age | Gender | Mean (SD) | Median (IQR) | Range | Min | Max | Mean (SD) | Median (IQR) | Range | Min | Max |
|---------|-------|--------|-------------|--------------|-------|-----|-----|-------------|--------------|-------|-----|-----|
| Control | 18-29 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 18-29 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 30-39 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 30-39 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 40-49 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 40-49 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 50-59 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 50-59 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 60-69 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 60-69 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 70-79 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 70-79 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 80+ | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Control | 80+ | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 18-29 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 18-29 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 30-39 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 30-39 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 40-49 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 40-49 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 50-59 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 50-59 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 60-69 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 60-69 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 70-79 | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 70-79 | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 80+ | Male | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |
| Stroke | 80+ | Female | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 | 1.00 (0.00) | 1.00 (0.00) | 0-1 | 0 | 1 |